Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 3/20 | 0.50 |
| ▸ | CA12 | O43570 | 2/20 | 0.42 |
| ▸ | CA1 | P00915 | 2/20 | 0.42 |
| ▸ | CA2 | P00918 | 2/20 | 0.42 |
| ▸ | CA3 | P07451 | 2/20 | 0.42 |
| ▸ | CA4 | P22748 | 2/20 | 0.42 |
| ▸ | CA6 | P23280 | 2/20 | 0.42 |
| ▸ | CA5A | P35218 | 2/20 | 0.42 |
| ▸ | CA7 | P43166 | 2/20 | 0.42 |
| ▸ | CA9 | Q16790 | 2/20 | 0.42 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.42 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.42 |
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | BLM | P54132 | 2/20 | 0.42 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | LPAR3 | Q9UBY5 | 4/20 | 0.38 |
| ▸ | LPAR2 | Q9HBW0 | 3/20 | 0.38 |
| ▸ | LPAR1 | Q92633 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11301547 | 1.00 | CYP3A4 (0.50) | CYP3A4CA12CA1CA2CA3 | |
| SCHEMBL28706 | 1.00 | CYP3A4 (0.50) | CYP3A4CA12CA1CA2CA3 | |
| SCHEMBL29395 | 0.89 | CYP3A4 (0.55) | CYP3A4TSHRLMNABLMALDH1A1 | |
| Octadecylamine SCHEMBL31542019 | 0.89 | CYP3A4 (0.64) | CYP3A4TSHRDNM1ALDH1A1LPAR3 | |
| SCHEMBL6953430 | 0.89 | TSHR (0.54) | CYP3A4TSHRDNM1ALDH1A1LPAR3 | |
| SCHEMBL16187636 | 0.86 | TSHR (0.56) | CYP3A4CA12CA1CA2CA9 | |
| SCHEMBL20738949 | 0.86 | CYP3A4 (0.43) | CYP3A4CA12CA1CA2CA3 | |
| Hydrochloric Acid SCHEMBL15619458 | 0.84 | TSHR (0.54) | CYP3A4TSHRLMNABLMDNM1 | |
| SCHEMBL6712517 | 0.82 | CA12 (0.40) | CYP3A4CA12CA1CA2CA3 | |
| SCHEMBL23631720 | 0.80 | ITPR3 (0.47) | CYP3A4CA12CA1CA2CA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 359 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2895607-B1 | DOUBLE-STRANDED OLIGONUCLEOTIDE MOLECULES TO DDIT4 AND METHODS OF USE THEREOF | QUARK PHARMACEUTICALS INC (US) | 2021-05-05 | — | — | EP | claimed |
| CN-106701758-B | Modulation of HSP47 expression | 日东电工株式会社 | 2020-02-07 | — | — | CN | claimed |
| EP-3434773-A2 | MODULATION OF HSP47 EXPRESSION | NITTO DENKO CORPORATION (JP) | 2019-01-30 | — | — | EP | claimed |
| US-10093923-B2 | Modulation of HSP47 expression | NITTO DENKO CORPORATION (JP) | 2018-10-09 | — | — | US | claimed |
| US-9611474-B2 | Double-stranded oligonucleotide molecules to DDIT4 and methods of use thereof | QUARK PHARMACEUTICALS, INC. (US) | 2017-04-04 | — | — | US | claimed |
| EP-3012324-A2 | MODULATION OF HSP47 EXPRESSION | Nitto Denko Corporation (JP) | 2016-04-27 | — | — | EP | claimed |
| US-20160108399-A1 | MODULATION OF HSP47 EXPRESSION | NITTO DENKO CORPORATION (JP) | 2016-04-21 | — | — | US | claimed |
| US-9206424-B2 | Modulation of HSP47 expression | NITTO DENKO CORPORATION (JP) | 2015-12-08 | — | — | US | claimed |
| EP-2509991-B1 | MODULATION OF HSP47 EXPRESSION | NITTO DENKO CORP (JP) | 2015-11-11 | — | — | EP | claimed |
| US-20150267194-A1 | DOUBLE-STRANDED OLIGONUCLEOTIDE MOLECULES TO DDIT4 AND METHODS OF USE THEREOF | Quark Pharmaceutical, Inc. (US) | 2015-09-24 | — | — | US | claimed |
| EP-2895607-A2 | DOUBLE-STRANDED OLIGONUCLEOTIDE MOLECULES TO DDIT4 AND METHODS OF USE THEREOF | Quark Pharmaceuticals, Inc. (US) | 2015-07-22 | — | — | EP | claimed |
| US-20140235695-A1 | MODULATION OF HSP47 EXPRESSION | NITTO DENKO CORPORATION | 2014-08-21 | — | — | US | claimed |
| US-8710209-B2 | Modulation of HSP47 expression | NITTO DENKO CORPORATION (JP) | 2014-04-29 | — | — | US | claimed |
| WO-2014043289-A2 | DOUBLE-STRANDED OLIGONUCLEOTIDE MOLECULES TO DDIT4 AND METHODS OF USE THEREOF | QUARK PHARMACEUTICALS, INC. (US) | 2014-03-20 | — | — | WO | claimed |
| US-20050074760-A1 | Enzymatic nucleic acids containing 5'-and/or 3'-cap structures | RIBOZYME PHARMACEUTICALS, INC. | 2005-04-07 | — | — | US | claimed |
| US-6586238-B1 | Modified ribozymes; useful for cleavage of RNA or single-stranded DNA; Resistance to exonuclease degradation | RIBOZYME PHARMACEUTICALS, INC. | 2003-07-01 | — | — | US | claimed |
| EP-1108724-A2 | Synthesis of methoxy nucleosides and enzymatic nucleic acid molecules | RIBOZYME PHARMACEUTICALS, INC. (US) | 2001-06-20 | — | — | EP | claimed |
| US-5998203-A | PARTICULARLY USEFUL FOR ENZYMATIC CLEAVAGE OF RNA OR SINGLE-STRANDED DNA. | RIBOZYME PHARMACEUTICALS, INC. (US) | 1999-12-07 | — | — | US | claimed |
| EP-0886641-A2 | SYNTHESIS OF METHOXY NUCLEOSIDES AND ENZYMATIC NUCLEIC ACID MOLECULES | RIBOZYME PHARMACEUTICALS, INC. (US) | 1998-12-30 | — | — | EP | claimed |
| WO-1997026270-A2 | SYNTHESIS OF METHOXY NUCLEOSIDES AND ENZYMATIC NUCLEIC ACID MOLECULES | RIBOZYME PHARMACEUTICALS, INC. (US) | 1997-07-24 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050074760-A1 | Enzymatic nucleic acids containing 5'-and/or 3'-cap structures | RNGTT, MTAP, RNASEL | CYP3A4 3987/4885CA12 2935/4885CA1 2860/4885 |
| US-10093923-B2 | Modulation of HSP47 expression | HSPA1A, HSPH1, HSPA8 | CYP3A4 4883/4885CA12 4376/4885CA1 4264/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.